MELISSA KLUTTS: Open Payments
NPI 1215445077 · COUNCIL BLUFFS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$735 in 40 payments from 15 companies in 2025. Trend: 2023 $569 · 2024 $536 · 2025 $735
Food & beverage: $735
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 12 | $197 |
| Novo Nordisk Inc | 4 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $69 |
| PFIZER INC. | 3 | $54 |
| Astellas Pharma US Inc | 2 | $46 |
| ABBVIE INC. | 3 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Lundbeck LLC | 2 | $36 |
| Amgen Inc. | 2 | $31 |
Products named: MOUNJARO, REXULTI, CAPLYTA, JARDIANCE, Veozah, GEMTESA, Rybelsus, Ozempic.
Industry payments across IA — which companies pay providers there.
